P505-15

• CAT Number: I001426
• CAS Number: 1370261-97-4
• Molecular Formula: C19H24ClN9O
• Molecular Weight: 429.91
• Purity: ≥95%
• Synonyms: 4-((3-(2H-1,2,3-triazol-2-yl)phenyl)amino)-2-(((1R,2R)-2-aminocyclohexyl)amino)pyrimidine-5-carboxamide hydrochloride
• Target: Cytoskeleton
• Solubility: DMSO: ≥ 33 mg/mL
• Storage: 3 years -20C powder
• IC50: 1 nM [1]
• IUPAC Name: 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide;hydrochloride
• InChI: InChI=1S/C19H23N9O.ClH/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28;/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27);1H/t15-,16+;/m0./s1
• InChIKey: RMNLLPXCNDZJMJ-IDVLALEDSA-N
• SMILES: C1CCC(C(C1)N)NC2=NC=C(C(=N2)NC3=CC=CC(=C3)N4N=CC=N4)C(=O)N.Cl

P505-15 (also known as Idelalisib)(CAT: I001426) is a potent and selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), a critical enzyme in the PI3K/Akt signaling pathway. This compound is widely used in research focused on hematological malignancies and autoimmune diseases, as PI3Kδ plays a pivotal role in B-cell receptor signaling and immune cell function. P505-15 effectively suppresses aberrant cell survival and proliferation, making it an invaluable tool for studying cancer biology and immune modulation. With high specificity and stability, it is suitable for in vitro and in vivo studies, supporting the development of targeted therapies.